13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q1 2023. See the latest, Q2 2026 →
Reported value
$1.80B
+4.7% on the quarter before
Positions
49
1 new · 3 sold out
Top 10
77.6%
of the value
Est. gain
+$25.8M
on stocks held all quarter
Est. return
+1.5%
on those stocks since Q4 2022
Positions as of Mar 31, 2023, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2022. Striped tiles are options.
Largest buys
Since Q4 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- CrowdStrike~$74.3MAdded · 3.8% → 8.9%+541,465 shares
- Gitlab Inc.~$21.9MAdded · 3.4% → 3.7%+639,207 shares
- Mondee Holdings Inc.~$205,567New · 0.0% → 0.0%+18,420 shares
- Invitae Corp~$26,515Added · 0.0% → 0.0%+19,641 shares
Largest sells
Since Q4 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Duolingo Inc.~$25.8MCut · 2.9% → 4.1%−180,620 shares
- Lyft Inc~$14.4MCut · 3.4% → 1.9%−1,555,509 shares
- New Relic Inc.~$5.1MSold out · 0.3% → 0.0%−91,132 shares
- Amplitude Inc~$2.3MSold out · 0.1% → 0.0%−189,447 shares
- Velo3d Inc~$1.0MSold out · 0.1% → 0.0%−572,400 shares
- Fulcrum Therapeutics Inc~$687,397Cut · 0.1% → 0.0%−241,190 shares
- Rani Therapeutics Hldgs Inc.~$318,042Cut · 0.2% → 0.1%−61,636 shares
Holdings
As of Mar 31, 2023. Changes are in shares against Dec 31, 2022, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UiPathCL A · shares 0% · price +38.2% | 13.7% | $247.0M | +$68.2M | ||||||||
| Prime Medicine, Inc.COM · shares 0% · price −33.8% | 9.1% | $163.4M | −$83.4M | ||||||||
| CrowdStrikeCL A · shares +87% · price +30.4% | 8.9% | $159.7M | +$19.9M | ||||||||
| Oscar Health Inc.CL A · shares 0% · price +165.9% | 8.7% | $157.2M | +$98.1M | ||||||||
| Verve Therapeutics Inc.COM · shares 0% · price −25.5% | 8.4% | $152.1M | −$52.0M | ||||||||
| Dexcom IncCOM · shares 0% · price +2.6% | 8.1% | $145.2M | +$3.7M | ||||||||
| Planet Labs PbcCOM CL A · shares 0% · price −9.7% | 7.0% | $125.5M | −$13.4M | ||||||||
| Eqrx Inc.COM · shares 0% · price −21.1% | 5.1% | $92.5M | −$24.8M | ||||||||
| SnowflakeCL A · shares 0% · price +7.5% | 4.6% | $82.6M | +$5.8M | ||||||||
| Duolingo Inc.CL A COM · shares −26% · price +100.5% | 4.1% | $74.7M | +$37.4M | ||||||||
| Gitlab Inc.CLASS A COM · shares +49% · price −24.5% | 3.7% | $66.3M | −$14.4M | ||||||||
| Freshworks IncCLASS A COM · shares 0% · price +4.4% | 3.4% | $62.0M | +$2.6M | ||||||||
| RobinhoodCOM CL A · shares 0% · price +19.3% | 2.7% | $47.9M | +$7.7M | ||||||||
| Lyft IncCL A COM · shares −30% · price −15.9% | 1.9% | $34.3M | −$6.5M | ||||||||
| Relay Therapeutics Inc.COM · shares 0% · price +10.2% | 1.4% | $25.8M | +$2.4M | ||||||||
| Desktop Metal Inc.COM CL A · shares 0% · price +69.1% | 1.4% | $25.4M | +$10.4M | ||||||||
| Benson Hill Inc.COMMON STOCK · shares 0% · price −55.5% | 0.98% | $17.7M | −$22.0M | ||||||||
| 23andme Holding Co.CLASS A COM · shares 0% · price +5.6% | 0.85% | $15.4M | +$808,414 | ||||||||
| Lyell Immunopharma Inc.COM · shares 0% · price −32.0% | 0.77% | $13.8M | −$6.5M | ||||||||
| Illumina Inc.COM · shares 0% · price +15.0% | 0.69% | $12.4M | +$1.6M | ||||||||
| Monte Rosa Therapeutics Inc.COM · shares 0% · price +2.4% | 0.63% | $11.4M | +$263,523 | ||||||||
| Rapt Therapeutics Inc.COM · shares 0% · price −7.3% | 0.55% | $9.9M | −$783,391 | ||||||||
| Beam Therapeutics Inc.COM · shares 0% · price −21.7% | 0.55% | $9.8M | −$2.7M | ||||||||
| Sana Biotechnology Inc.COM · shares 0% · price −17.2% | 0.51% | $9.2M | −$1.9M | ||||||||
| Invivyd Inc.COM · shares 0% · price −20.0% | 0.38% | $6.8M | −$1.7M | ||||||||
| Total · 49 positions | 100% | $1.80B | +$25.8M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2022 to Q1 2023: 48 stocks held throughout, up $25.8M (+1.5%).
- Oscar Health Inc.+$98.1M+166%
- UiPath+$68.2M+38%
- Duolingo Inc.+$37.4M+100%
- CrowdStrike+$19.9M+30%
- Desktop Metal Inc.+$10.4M+69%
- Gitlab Inc.−$14.4M−25%
- Benson Hill Inc.−$22.0M−55%
- Eqrx Inc.−$24.8M−21%
- Verve Therapeutics Inc.−$52.0M−25%
- Prime Medicine, Inc.−$83.4M−34%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |